Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer

Bharti Garg, Bhuwan Giri, Kaustav Majumder, Vikas Dudeja, Sulagna Banerjee, Ashok Saluja

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

β-Catenin/Wnt signaling pathway is critically regulated in a normal cell by a number of post-translational modifications. In pancreatic cancer however, aberrant activation of this pathway plays a significant role in tumor progression and metastasis. Though a number of studies have focused on understanding Wnt signaling pathway in pancreatic cancer, there has been no systematic study to evaluate molecules that may be affecting this pathway. In the current study, we used a diterpene triepoxide, triptolide, to inhibit post-translational modifications in Wnt pathway and evaluated how this compound may be affecting the intricate signaling that regulates cell proliferation in pancreatic cancer. Our results showed that triptolide inhibits the activation of WNT1, FZD1, and disheveled (DSH) in pancreatic cancer cell lines MIA PaCa-2 and S2-VP10 by inhibiting the phosphorylation of LRP6 and simultaneously blocked translocation of β-catenin to the nucleus by inhibiting its glycosylation. Additionally, inhibition of post-translational modification of the Wnt-signaling pathway also demonstrated regression of tumor growth in a Syngenic Tumor Implantation Model (STIM). Interestingly, these findings suggest Wnt signaling is a vital molecular pathway in pancreatic cancer and may be amenable to targeted drug therapy.

Original languageEnglish (US)
Pages (from-to)64-72
Number of pages9
JournalCancer Letters
Volume388
DOIs
StatePublished - Mar 1 2017

Fingerprint

Catenins
Wnt Signaling Pathway
Post Translational Protein Processing
Pancreatic Neoplasms
Neoplasms
Diterpenes
Glycosylation
Cell Count
Phosphorylation
Cell Proliferation
Neoplasm Metastasis
Drug Therapy
Cell Line
Growth

Keywords

  • OGT
  • Pancreatic tumor
  • STIM model
  • TCF/LEF1
  • Wnt
  • β-Catenin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer. / Garg, Bharti; Giri, Bhuwan; Majumder, Kaustav; Dudeja, Vikas; Banerjee, Sulagna; Saluja, Ashok.

In: Cancer Letters, Vol. 388, 01.03.2017, p. 64-72.

Research output: Contribution to journalArticle

@article{c1bad441968442c9b77bc15a234bd8d7,
title = "Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer",
abstract = "β-Catenin/Wnt signaling pathway is critically regulated in a normal cell by a number of post-translational modifications. In pancreatic cancer however, aberrant activation of this pathway plays a significant role in tumor progression and metastasis. Though a number of studies have focused on understanding Wnt signaling pathway in pancreatic cancer, there has been no systematic study to evaluate molecules that may be affecting this pathway. In the current study, we used a diterpene triepoxide, triptolide, to inhibit post-translational modifications in Wnt pathway and evaluated how this compound may be affecting the intricate signaling that regulates cell proliferation in pancreatic cancer. Our results showed that triptolide inhibits the activation of WNT1, FZD1, and disheveled (DSH) in pancreatic cancer cell lines MIA PaCa-2 and S2-VP10 by inhibiting the phosphorylation of LRP6 and simultaneously blocked translocation of β-catenin to the nucleus by inhibiting its glycosylation. Additionally, inhibition of post-translational modification of the Wnt-signaling pathway also demonstrated regression of tumor growth in a Syngenic Tumor Implantation Model (STIM). Interestingly, these findings suggest Wnt signaling is a vital molecular pathway in pancreatic cancer and may be amenable to targeted drug therapy.",
keywords = "OGT, Pancreatic tumor, STIM model, TCF/LEF1, Wnt, β-Catenin",
author = "Bharti Garg and Bhuwan Giri and Kaustav Majumder and Vikas Dudeja and Sulagna Banerjee and Ashok Saluja",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.canlet.2016.11.026",
language = "English (US)",
volume = "388",
pages = "64--72",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Modulation of post-translational modifications in β-catenin and LRP6 inhibits Wnt signaling pathway in pancreatic cancer

AU - Garg, Bharti

AU - Giri, Bhuwan

AU - Majumder, Kaustav

AU - Dudeja, Vikas

AU - Banerjee, Sulagna

AU - Saluja, Ashok

PY - 2017/3/1

Y1 - 2017/3/1

N2 - β-Catenin/Wnt signaling pathway is critically regulated in a normal cell by a number of post-translational modifications. In pancreatic cancer however, aberrant activation of this pathway plays a significant role in tumor progression and metastasis. Though a number of studies have focused on understanding Wnt signaling pathway in pancreatic cancer, there has been no systematic study to evaluate molecules that may be affecting this pathway. In the current study, we used a diterpene triepoxide, triptolide, to inhibit post-translational modifications in Wnt pathway and evaluated how this compound may be affecting the intricate signaling that regulates cell proliferation in pancreatic cancer. Our results showed that triptolide inhibits the activation of WNT1, FZD1, and disheveled (DSH) in pancreatic cancer cell lines MIA PaCa-2 and S2-VP10 by inhibiting the phosphorylation of LRP6 and simultaneously blocked translocation of β-catenin to the nucleus by inhibiting its glycosylation. Additionally, inhibition of post-translational modification of the Wnt-signaling pathway also demonstrated regression of tumor growth in a Syngenic Tumor Implantation Model (STIM). Interestingly, these findings suggest Wnt signaling is a vital molecular pathway in pancreatic cancer and may be amenable to targeted drug therapy.

AB - β-Catenin/Wnt signaling pathway is critically regulated in a normal cell by a number of post-translational modifications. In pancreatic cancer however, aberrant activation of this pathway plays a significant role in tumor progression and metastasis. Though a number of studies have focused on understanding Wnt signaling pathway in pancreatic cancer, there has been no systematic study to evaluate molecules that may be affecting this pathway. In the current study, we used a diterpene triepoxide, triptolide, to inhibit post-translational modifications in Wnt pathway and evaluated how this compound may be affecting the intricate signaling that regulates cell proliferation in pancreatic cancer. Our results showed that triptolide inhibits the activation of WNT1, FZD1, and disheveled (DSH) in pancreatic cancer cell lines MIA PaCa-2 and S2-VP10 by inhibiting the phosphorylation of LRP6 and simultaneously blocked translocation of β-catenin to the nucleus by inhibiting its glycosylation. Additionally, inhibition of post-translational modification of the Wnt-signaling pathway also demonstrated regression of tumor growth in a Syngenic Tumor Implantation Model (STIM). Interestingly, these findings suggest Wnt signaling is a vital molecular pathway in pancreatic cancer and may be amenable to targeted drug therapy.

KW - OGT

KW - Pancreatic tumor

KW - STIM model

KW - TCF/LEF1

KW - Wnt

KW - β-Catenin

UR - http://www.scopus.com/inward/record.url?scp=85003816102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003816102&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2016.11.026

DO - 10.1016/j.canlet.2016.11.026

M3 - Article

C2 - 27919787

AN - SCOPUS:85003816102

VL - 388

SP - 64

EP - 72

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -